More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$12.35B
EPS
1.39
P/E ratio
45.1
Price to sales
3.66
Dividend yield
--
Beta
0.242218
Previous close
$61.46
Today's open
$64.83
Day's range
$62.20 - $64.92
52 week range
$49.26 - $66.28
show more
CEO
Alexander Hardy
Employees
3221
Headquarters
San Rafael, CA
Exchange
Nasdaq Global Select
Shares outstanding
193573759
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
Zacks Investment Research • 18 hours ago

BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical NASDAQ: BMRN reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call.
MarketBeat • Aug 6, 2026

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 7, 2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share (EPS) Addition of GALAFOLD® and POMBILITI® + OPFOLDA®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
PRNewsWire • Aug 6, 2026

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.44 per share a year ago.
Zacks Investment Research • Aug 6, 2026

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Aug 6, 2026

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m.
PRNewsWire • Jul 30, 2026

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Jul 27, 2026

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense expertise Investigational antisense oligonucleotide (ASO) aims to address the underlying genetic cause of this serious neurodevelopmental condition SAN RAFAEL, Calif. and SAN DIEGO, July 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit organization, today announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease, antisense oligonucleotide (ASO) medicine for people living with ReNU syndrome, a serious and rare neurodevelopmental condition caused by variants in the RNU4-2 gene.
PRNewsWire • Jul 27, 2026

BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
Seeking Alpha • Jul 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BioMarin Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.